Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $60.8571.
KNSA has been the subject of a number of research analyst reports. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Monday, May 4th. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th.
Get Our Latest Stock Report on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Price Performance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company’s revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 earnings per share. On average, research analysts expect that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current fiscal year.
Insider Transactions at Kiniksa Pharmaceuticals International
In related news, CAO Michael R. Megna sold 6,625 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the transaction, the chief accounting officer directly owned 27,418 shares of the company’s stock, valued at $1,280,146.42. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at $628,554.60. This trade represents a 51.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 653,301 shares of company stock worth $34,046,073. Insiders own 51.98% of the company’s stock.
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
A number of hedge funds have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC grew its stake in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $31,000. KBC Group NV purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $34,000. Smartleaf Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.
Featured Stories
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
